Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €121.40 EUR
Change Today +0.78 / 0.65%
Volume 0.0
TEN On Other Exchanges
SIX Swiss Ex
As of 2:22 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

tecan group ag-reg (TEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - €122.67
52 Week Low
10/16/14 - €74.60
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TECAN GROUP AG-REG (TEN)

Related News

No related news articles were found.

tecan group ag-reg (TEN) Related Businessweek News

No Related Businessweek News Found

tecan group ag-reg (TEN) Details

Tecan Group Ltd. provides laboratory instruments and automated workflow solutions for pharmaceutical and biotechnology companies, government research institutions and universities, diagnostic laboratories, and various applied markets. The company operates in two segments, Life Sciences Business and Partnering Business. It develops, produces, and distributes automation solutions, including instruments, software packages, numerous configurable modules, and special application knowhow, as well as consulting, services, and consumables. The company offers liquid handling platforms, which are used to pipette fluids with optimum precision and automate laborious and repetitive manual procedures; a range of bioanalytical instruments, such as microplate readers and washers that allows reactions to be monitored or analytes to be measured; and immunoassays for life science research and routine clinical diagnostics. It also develops and manufactures original equipment manufacturer instruments and components; and supplies laboratory instrument manufacturers with various components, such as precision pumps, valves, robotic arms, and development software under the Cavro brand. In addition, the company offers dedicated automation solutions comprising Dako Omnis, which is used in tissue-based cancer diagnostics; platform-based automation solutions; and pipette tips that acts as a component of a validated workflow solution, as well as detection instruments. Further, it provides ORTHO VISION analyzer, a diagnostics instrument that is used for blood typing; and determining other blood parameters. Tecan Group Ltd. distributes its products through its own market organization and distributors in approximately 50 countries worldwide. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

1,100 Employees
Last Reported Date: 03/27/15
Founded in 1980

tecan group ag-reg (TEN) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: SFr.1.0M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: SFr.455.0K
Compensation as of Fiscal Year 2013.

tecan group ag-reg (TEN) Key Developments

Tecan Group Ltd. to Report Fiscal Year 2014 Final Results on Mar 27, 2015

Tecan Group Ltd. announced that they will report fiscal year 2014 final results on Mar 27, 2015

The Tecan Grou Announces Board Changes

The Tecan Group announced that its Board of Directors will propose the election of Lars Holmqvist as a new member of the Board at the Annual General Meeting. Most recently, he was President of the Life Sciences and Diagnostics Group and Senior Vice President at Agilent Technologies Inc. After serving on Tecan's Board of Directors for four years, Erik Wallden will not seek reelection at this year's Annual General Meeting.

Tecan Group AG Announces Earnings Results for the Second Half and Full Year of 2014; Provides Earnings Guidance for the Year 2015

Tecan Group AG announced earnings results for the second half and full year of 2014. For the second half, the company reported sales rose by 10.3% in local currencies and by 10.2% in Swiss francs, corresponding to organic sales growth of 5.8% in local currencies and 5.7% in Swiss francs. For the full year, the company reported sales reached CHF 399.5 million compared to CHF 388.3 million a year ago and were therefore 4.2% above the prior-year level in local currency terms and 2.9% in Swiss francs. Including acquisition-related costs, operating profit before interest and taxes (EBIT) increased by 4.4% to CHF 57.2 million compared to CHF 54.8 million a year ago, corresponding to an EBIT margin of 14.3% of sales. Net profit reported for the year 2014 reached CHF 40.2 million compared to CHF 45.7 million a year ago. The decline is the result of a lower financial result attributable to currency hedging measures as the US dollar significantly appreciated towards year end. Earnings per share are CHF 3.63 compared to CHF 4.16 a year ago. Cash flow from operating activities further improved to CHF 48.2 million compared to CHF 27.9 million a year ago, as the prefinancing of an OEM development project is coming to an end and a first reimbursement of development costs was received from the partner. For the year 2015, total Group sales are forecast to increase with a double-digit rate in local currencies. This strong growth will be driven by a continued ramp up of major Partnering Business platforms and further supported by introductions of additional versions of the Fluent platform, the first launch of the Spark(TM) multimode reader platform and a full-year contribution of IBL International. The EBITDA margin is expected to expand by more than 100 basis points, with the EBIT margin to also further increase. Before effects related to the acquisition of IBL International, this corresponds to an EBIT margin above 15%. These expectations regarding profitability are based on an average exchange rate forecast for full-year 2015 CHF 1.05 and one US dollar equaling CHF 0.92 and exclude further acquisitions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TEN:GR €121.40 EUR +0.78

TEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation TEN Industry Range
Price/Earnings 36.8x
Price/Sales 3.6x
Price/Book 4.0x
Price/Cash Flow 37.4x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TECAN GROUP AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at